Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 25:12:197-205.
doi: 10.2147/JBM.S300717. eCollection 2021.

Possible Role of CD11a in Primary Immune Thrombocytopenia Patients on Immunosuppressive Therapy

Muhamad R Abdel Hameed  1   2 , Howiada A Nafady  1   2 , Mona Ibrahim Mostafa  3 , Douaa Sayed  4 , Ahmad A Obiedallah  5
Affiliations

Possible Role of CD11a in Primary Immune Thrombocytopenia Patients on Immunosuppressive Therapy

Muhamad R Abdel Hameed et al. J Blood Med. .

Abstract

Background and objectives: Immune thrombocytopenia (ITP) is one of the autoimmune diseases that presented by thrombocytopenia and increased risk of bleeding. Etiology of immune thrombocytopenia (ITP) is very complex. Lymphocyte function associated antigen-1 (LFA-1) plays important role in ITP. The aim of this study was evaluation of expression of CD11a on lymphocytes to explore its possible role in primary ITP patients also, regarding severity and response to immunosuppressive treatment.

Patients and methods: This is a cross-sectional case-control study. Forty adult patients aged (18:58) years, 29 females and 11 males were enrolled as newly diagnosed primary ITP. Forty age and sex matched control subjects were randomly selected. The expression of CD11a on lymphocyte subpopulations (CD3+ T cells, CD3+CD4+ T cells and CD19+ B cells) was analyzed by flowcytometry at the start of the study and after 6 months of follow-up.

Results: The mean fluorescence intensity (MFI) of CD11a on CD3+ T and CD19+ B lymphocytes was significantly highly increased in ITP patients compared to healthy controls while MFI of CD11a on CD3+ CD4+Tclls was non-significant. MFI of CD11a on CD3+ and CD19+ B lymphocytes showed non-significant elevation with platelet count or bleeding score. MFI of CD11a on CD3+ showed significant highly increased level in refractory ITP compared with responder cases.

Conclusion: CD11a had possible role in the pathogenesis of ITP. Immunosuppressive therapy in ITP did not affect the level of CD11a expression on T and B lymphocytes. Levels of CD11a do not reflect the severity of ITP neither platelet count nor bleeding score. Increased MFI of CD11a in CD3+T lymphocytes of ITP patients may cause resistance to immunosuppressive therapy.

Keywords: B cells; CD11a; LFA-1; Primary immune thrombocytopenia; T cells; immunosuppressive therapy.

PubMed Disclaimer

Conflict of interest statement

All authors declare that they have no conflicts of interest for this work.

Figures

Figure 1
Figure 1
The expression of CD11a on lymphocyte subsets in ITP patient before treatment. (A) Lymphocytes were gated by flow cytometry (P1). (B) CD3+ cells gated by flow cytometry (P2). (B*) MFI of CD11a gated on CD3+ cells (P3). (C) Expression of CD11a on CD3+CD4+ T cells (P6). (C*) MFI of CD11a gated on CD3+CD4+ T cells (P7). (D) Expression of CD11a on CD19+ cells (P4). (D*) MFI of CD11a gated on CD19+ cells (P5).
Figure 2
Figure 2
The expression of CD11a on lymphocyte subsets after 6 months follow-up in ITP patient whose response to treatment. (A) Lymphocytes were gated by flow cytometry (P1). (B) CD3+ cells gated by flow cytometry (P2). (B*) MFI of CD11a gated on CD3+ cells (P3). (C) Expression of CD11a on CD3+CD4+ T cells (P6). (C*) MFI of CD11a gated on CD3+CD4+ T cells (P7). (D) Expression of CD11a on CD19+ cells (P4). (D*) MFI of CD11a gated on CD19+ cells (P5).
Figure 3
Figure 3
Pattern of bleeding in ITP patients at presentation.
See this image and copyright information in PMC

References

    1. McMillan R. Immune-mediated thrombocytopenias focus on chronic immune thrombocytopenic purpura. Semin Hematol. 2007;44:1–2. doi:10.1053/j.seminhematol.2007.11.001 - DOI - PubMed
    1. Ahn YS, Horstman LL. Idiopathic thrombocytopenic purpura: pathophysiology and management. Int J Hematol. 2002;76(2):123–131. doi:10.1007/BF03165102 - DOI - PubMed
    1. Kawana M, Ikeda Y. The role of autoreactive T Cells in the pathogenesis of idiopathic thrombocytopenic purpura. Int J Hematol. 2005;81:106–112. doi:10.1532/IJH97.04176 - DOI - PubMed
    1. Kim SY, Solomon DH. Tumor necrosis factor blockade and the risk of viral infections. Nat Rev Rheumatol. 2010;6(3):165–174. doi:10.1038/nrrheum.2009.279 - DOI - PMC - PubMed
    1. Targownik LE, Bernstein CN. Infectious and malignant complications of TNF inhibitor therapy in IBD. Am J Gastroenterol. 2013;108(12):1835–1842. doi:10.1038/ajg.2013.294 - DOI - PubMed